HanchorBio to Attend BIO International Convention 2026 to Advance Global Partnering Opportunities
Participation in BIO International Convention 2026 supports HanchorBio’s continued engagement with global biotech, pharmaceutical, and investment partners
[Taipei, Shanghai, San Francisco | June 19, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that Dr. Yuehua Cong, Chief Business Officer, will attend BIO International Convention 2026, taking place June 22–25, 2026, in San Diego, California.
BIO International Convention is one of the world’s largest biotechnology events, bringing together global leaders from biotechnology, pharmaceuticals, investment, academia, government, and patient advocacy groups to explore innovation, partnerships, and business development opportunities.
Event Information
- Event: BIO International Convention 2026
- Date: June 22–25, 2026
- Location: San Diego Convention Center, San Diego, California, USA
Through BIO Partnering™, HanchorBio looks forward to engaging with global biotech, pharmaceutical, and investment partners. The BIO Partnering™ platform is designed to support efficient one-on-one meeting requests and scheduling, helping participants identify and connect with potential business development partners.
HanchorBio will leverage BIO International Convention 2026 to showcase the progress of its clinically validated innate immune platform and growing pipeline across oncology and autoimmune diseases. The Company looks forward to engaging with global pharmaceutical, biotechnology, and investment partners to explore licensing, co-development, and other strategic collaboration opportunities. With multiple clinical-stage programs advancing across key disease areas, HanchorBio believes the meeting provides an important platform to expand global partnering discussions and support the continued development of its international business strategy.
Guided by its mission of “Reimagining Immunotherapy for Patients Worldwide,” HanchorBio remains committed to advancing Fc-based biologics designed to address important unmet medical needs in cancer and immune-mediated diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.